To determine whether thrombospondin-1 is the driving force of dissecting AAA pathogenesis in the absence of LH1, we used TAX2, a CD47-derived cyclic peptide that targets thrombospondin-1, selectively prevents the thrombospondin-1:CD47 interaction and blocks the downstream signaling pathway. This evidence concerns the gene THBS1 and triple-A syndrome.